Valeritas (NSDQ:VLRX) touted positive findings today from an analysis of its V-Go wearable insulin delivery system with a weekly physician-driven insulin titration algorithm.
Two-thirds of patients met their glycemic targets, the company said, and patient-reported hypoglycemia dropped by the end of the study.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas touts study of V-Go insulin delivery device paired with insulin titration algorithm appeared first on MassDevice.